NPPA demand notice for alleged overcharging of scheduled formulations

Regulatory & Legal View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹2370.00

prior close

₹2380.90

announcement price

In-mkt

timing

Nifty Midcap 150market-0.5%+0.4% vs market

Pharmaceuticals peers, median of 163sector-0.6%+0.5% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-0.5+0.4-0.6+0.5

Next day

-0.5-0.8+0.4-0.3-0.1

+3.4-0.4+3.8+0.4+3.0

+2.5-0.2+2.7+0.0+2.5

+1.6+0.3+1.3+0.2+1.4

+1.6+0.1+1.5+1.2+0.3

+1.6+0.2+1.4+0.1+1.5

15d

+3.6+0.4+3.2+0.8+2.8

+7.8+0.3+7.5+0.8+7.0

+26.9+2.9+24.0+1.2+25.7

+18.5-1.9+20.4+5.4+13.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GSK Pharmaceuticals received a demand notice dated 24 June 2026 from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging of scheduled formulations. Total demand is about Rs 3.54 crore, comprising Rs 1.22 crore as alleged overcharge and Rs 2.31 crore as interest. The company states no impact on financial operations and will file an appeal against the demand order.

Likely market impact

Small demand relative to company size; firm will appeal; no immediate hit to financials or operations stated.